IP Library › Granted Patent US 12,280,254
Granted Patent B2
US 12,280,254 · App. 18/405,162 · Granted Apr 22, 2025

Apparatus and method for microcurrent-stimulation therapy

Inventors: Marshall T. Masko (Minnetonka, MN); Blair P. Mowery (College Grove, TN); John C. Velure (Minnetonka, MN); Charles A. Lemaire (Apple Valley, MN)
Assignee: i-Lumen Scientific, Inc.
A61N1/36046A61N1/0456A61N1/3603A61N5/06G06F21/6245G16H10/60G16H20/30G16H40/67A61N2005/0648
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,254
App. No.
18/405,162
Granted
Apr 22, 2025
Kind
B2
Abstract

A system and method for applying stimulation therapy to a patient, the system including a first stimulation strip that includes a first elongated portion configured to be placed on the upper eyelid of the first eye of the patient and a second elongated portion configured to be placed on the lower eyelid of the first eye of the patient, wherein the first stimulation strip includes: a first plurality of individually controlled electrodes configured to deliver a microcurrent stimulation therapy to the patient, a first plurality of individually controlled light emitters configured to deliver light stimulation therapy to the patient, and a first plurality of individually controlled heat sources configured to deliver heat therapy to the patient; and a controller operatively coupled to the first stimulation strip and configured to control delivery of the microcurrent stimulation therapy, the light stimulation therapy, and the heat therapy.

Claims (59)

1. A system for application of a stimulation therapy to a patient, the system comprising:

a first set of one or more light emitters, wherein each of the one or more light emitters are configured to deliver light-stimulation therapy to a first eye of the patient;

a first substrate comprising one or more electrodes, wherein each of the one or more electrodes are configured to deliver microcurrent stimulation therapy to the first eye of the patient; and

a controller configured to control delivery of the microcurrent stimulation therapy via the one or more electrodes of the first substrate and the light-stimulation therapy via the one or more light emitters of the first set to the first eye of the patient.

2. The system of claim 1 , wherein each of the one or more electrodes are individually controllable by the controller.

3. The system of claim 1 , further comprising a unique identifier on the substrate, and wherein the controller is configured to control a specific therapy regimen specified for the patient based on the unique identifier.

4. The system of claim 1 , further comprising:

a second set of one or more light emitters, wherein each of the one or more light emitters are configured to deliver light-stimulation therapy to a second eye of the patient; and

a second substrate comprising second one or more electrodes, wherein each of the second one or more electrodes are configured to deliver microcurrent stimulation therapy to the second eye of the patient, and

wherein the controller is further configured to control delivery of the microcurrent stimulation therapy via the second one or more electrodes of the second substrate and the light stimulation therapy via the one or more light emitters of the second set to the second eye of the patient.

5. The system of claim 4 , wherein the controller is configured to cause delivery of the light-stimulation therapy and the microcurrent stimulation therapy to both the first eye and the second eye during the first time period.

6. The system of claim 4 , wherein the controller is configured to cause delivery of the microcurrent stimulation therapy and the light-stimulation therapy in a sequential manner such that each stimulation therapy begins at a different start time to the first eye of the patient during a first time period and at a different start time to the second eye of the patient during a second time period after the first time period.

7. The system of claim 4 , wherein the controller is configured to cause delivery of both the microcurrent stimulation therapy and the light-stimulation therapy alternately to the first eye of the patient and then to the second eye of the patient.

8. The system of claim 4 , wherein the controller is configured to cause delivery of the microcurrent stimulation therapy alternately to the first eye of the patient and then to the second eye of the patient, and configured to cause delivery of the light-stimulation therapy alternately to the second eye and then to the first eye.

9. The system of claim 4 , wherein the controller is configured to deliver the microcurrent stimulation therapy and the light-stimulation therapy simultaneously to both the first eye and the second eye of the patient during a first time period.

10. The system of claim 1 , wherein each of the one or more electrodes includes a respective gelled contact point on the substrate.

11. The system of claim 1 , wherein the first set of one or more light emitters is included in a head-mounted display device configured to be mounted on the patient's head, wherein the display device includes an internal stimulation display configured to be visible to the patient when the display device is mounted on the patient, and wherein the controller is configured to control delivery of the light-stimulation therapy from the display device.

12. The system of claim 11 , wherein the light-stimulation therapy comprises red wavelengths in a range of 600 nm to 700 nm.

13. The system of claim 12 , wherein the controller is further configured to control the display device to cause formation of one or more points of light that move across a visual field of the patient to urge the patient to move their eyes to follow the movement of the one or more points of light to orient eyes of the patient in different positions during the light-stimulation therapy.

14. The system of claim 1 , wherein the first set of one or more light emitters is included on the first substrate.

15. The system of claim 1 , wherein the light-stimulation therapy is delivered to both eyes of the patient simultaneously.

16. The system of claim 1 , wherein the microcurrent stimulation therapy is delivered to both eyes of the patient simultaneously.

17. The system of claim 1 , wherein the system is configured to deliver a combination of microcurrent stimulation therapy and light-stimulation therapy, wherein the microcurrent stimulation therapy is delivered to the patient in a sequential manner with the light-stimulation therapy such that each therapy begins at a different start time.

18. An apparatus for applying stimulation therapy to a patient, the apparatus comprising:

a first set of one or more individually controlled light emitters;

a first substrate, wherein the first substrate comprises a first plurality of individually controlled electrodes;

means for delivering a first microcurrent stimulation therapy to the first eye of the patient via the first plurality of individually controlled electrodes; and

means for delivering a first light-stimulation therapy to the first eye of the patient via the first set of one or more individually controlled light emitters.

19. A method for applying stimulation therapy to a patient, the method comprising:

providing a first set of light emitters;

providing a first substrate comprising one or more electrodes;

delivering a first microcurrent stimulation therapy to a first eye of the patient via the one or more electrodes; and

delivering a first light-stimulation therapy to the first eye of the patient via the first set of one or more light emitters.

20. The method of claim 19 , wherein each respective electrode of the one or more electrodes contacts the patient at a respective contact pressure, the method further comprising:

selectively maintaining the respective contact pressure of each respective electrode at a value in a range of about two (2) ounces per square inch to about fifteen (15) pounds per square inch.

21. The method of claim 19 , further comprising delivering the first microcurrent stimulation therapy and the first light-stimulation therapy simultaneously.

22. The method of claim 19 , further comprising:

providing a stimulator configured to generate the microcurrent stimulation therapy delivered by the one or more electrodes;

operatively coupling the stimulator to the one or more electrodes; and

placing the stimulator on the patient.

23. The method of claim 19 , further comprising:

providing a stimulator configured to generate the microcurrent stimulation therapy delivered by the one or more electrodes;

operatively coupling the stimulator to the one or more electrodes; and

placing the stimulator in a location separate from the patient.

24. The method of claim 19 , further comprising generating an indicative sound to indicate a characteristic of the first microcurrent stimulation therapy.

25. The method of claim 19 , further comprising:

providing a second set of one or more light emitters;

providing a second substrate comprising a second one or more electrodes;

delivering a second microcurrent stimulation therapy to a second eye of the patient via the second one or more electrodes; and

delivering a second light-stimulation therapy to the second eye of the patient via the second set of one or more light emitters.

26. The method of claim 25 , wherein the delivering of the first microcurrent stimulation therapy to the first eye occurs simultaneously with the delivering of the second microcurrent stimulation therapy to the second eye.

27. The method of claim 25 , further comprising:

receiving a unique identifier from the first substrate; and

using the unique identifier by the controller to control a specific therapy regimen specified for the patient.

28. The method of claim 25 , further comprising:

providing a head-mounted display device configured to be placed on the patient's head, wherein the display device includes an internal stimulation display configured to be seen by the patient when the display device is on the patient; and

delivering a light-stimulation output from the display device onto the patient's retina.

29. The method of claim 28 , wherein the light-stimulation output includes red wavelengths in a range of 600 nm to 700 nm.

30. The method of claim 28 , wherein delivering of the light-stimulation output includes moving one or more points of light across the patient's visual field to urge the patient to move their eyes to follow the movement of the one or more points of light to orient the eyes in different positions during the therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2024
From: MASKO, MARSHALL T.; MOWERY, BLAIR P.; VELURE, JOHN C.; LEMAIRE, CHARLES A.
To: I-LUMEN SCIENTIFIC, INC.
Reel/Frame 066137/0056 →
CERTIFICATE OF CONVERSION MINNESOTA CORPORATION TO DELAWARE CORPORATION Recorded Jan 16, 2024
From: I-LUMEN SCIENTIFIC, INC.
To: I-LUMEN SCIENTIFIC, INC.
Reel/Frame 066337/0788 →
Continuity (5)
Continuation 18144812 · May 8, 2023
Continuation 17866259 · Jul 15, 2022
Continuation 17416024
Provisional Application 62783116 · Dec 20, 2018
Related Publication 20240216687A1 · Jul 4, 2024
References Cited (101)
US 3376870A · Yamamoto et al. · 1968 [cited by applicant]
US 3669119A · Symmes · 1972 [cited by applicant]
US 4018218A · Carlson et al. · 1977 [cited by applicant]
US 4989605A · Rossen · 1991 [cited by applicant]
US 5522864A · Wallace et al. · 1996 [cited by applicant]
US 5730720A · Sites et al. · 1998 [cited by applicant]
US 5843147A · Testerman et al. · 1998 [cited by applicant]
US 6035236A · Jarding et al. · 2000 [cited by applicant]
US 6275735B1 · Jarding et al. · 2001 [cited by applicant]
US 6350275B1 · Vreman et al. · 2002 [cited by applicant]
US 6385727B1 · Cassagnol et al. · 2002 [cited by applicant]
US 6445955B1 · Michelson et al. · 2002 [cited by applicant]
US 6454709B1 · Kleinschmidt et al. · 2002 [cited by applicant]
US 6516227B1 · Meadows et al. · 2003 [cited by applicant]
US 6587728B2 · Fang et al. · 2003 [cited by applicant]
US 6636754B1 · Baura et al. · 2003 [cited by applicant]
US 6792314B2 · Byers et al. · 2004 [cited by applicant]
US 6993387B2 · Connelly et al. · 2006 [cited by applicant]
US 7062319B1 · Ihme et al. · 2006 [cited by applicant]
US 7069084B2 · Yee · 2006 [cited by applicant]
US 7158834B2 · Paul, Jr. · 2007 [cited by applicant]
US 7215989B1 · Burks · 2007 [cited by applicant]
US 7239910B2 · Tanner · 2007 [cited by applicant]
US 7251528B2 · Harold · 2007 [cited by applicant]
US 7326181B2 · Katims · 2008 [cited by applicant]
US 7771342B2 · Rademacher et al. · 2010 [cited by applicant]
US 7883536B1 · Bendett et al. · 2011 [cited by applicant]
US 8116841B2 · Bly et al. · 2012 [cited by applicant]
US 8160696B2 · Bendett et al. · 2012 [cited by applicant]
US 8494625B2 · Hargrove · 2013 [cited by applicant]
US 8554324B2 · Brocke · 2013 [cited by applicant]
US 8560077B2 · Feinstein · 2013 [cited by applicant]
US 8639345B2 · Eipper et al. · 2014 [cited by applicant]
US 8731657B1 · Shambayati et al. · 2014 [cited by applicant]
US 8781594B2 · Lindenthaler · 2014 [cited by applicant]
US 8956274B2 · Schneider et al. · 2015 [cited by applicant]
US 8958883B2 · Mueller et al. · 2015 [cited by applicant]
US 8996131B1 · Owen et al. · 2015 [cited by applicant]
US 9061148B2 · Bachinski et al. · 2015 [cited by applicant]
US 9199080B2 · Gekeler et al. · 2015 [cited by applicant]
US 9308363B2 · Goroszeniuk et al. · 2016 [cited by applicant]
US 9387321B2 · Greenberg et al. · 2016 [cited by applicant]
US 9474446B2 · Amann et al. · 2016 [cited by applicant]
US 9510972B2 · Badawi · 2016 [cited by applicant]
US 9566427B2 · Wagner · 2017 [cited by applicant]
US 9579040B2 · Rafferty et al. · 2017 [cited by applicant]
US 9675794B2 · Miller · 2017 [cited by applicant]
US 9719977B2 · Korb et al. · 2017 [cited by applicant]
US 9724230B2 · Badawi · 2017 [cited by applicant]
US 9918875B2 · Ha et al. · 2018 [cited by applicant]
US 9977865B1 · LaBorde · 2018 [cited by applicant]
US 9999766B2 · Elliott · 2018 [cited by applicant]
US 10016600B2 · Creasey et al. · 2018 [cited by applicant]
US 10080683B2 · Ha et al. · 2018 [cited by applicant]
US 10124160B2 · Dorvall et al. · 2018 [cited by applicant]
US 10272256B2 · Toyos · 2019 [cited by applicant]
US 10376691B2 · De Toni et al. · 2019 [cited by applicant]
US 10391312B2 · Mowery et al. · 2019 [cited by applicant]
US 10456579B2 · Salazar · 2019 [cited by applicant]
US 10507135B2 · Ha et al. · 2019 [cited by applicant]
US 10520997B2 · Sen et al. · 2019 [cited by applicant]
US 10525255B2 · Wingeier et al. · 2020 [cited by applicant]
US 10537476B2 · Ha et al. · 2020 [cited by applicant]
US 10543124B2 · Ha · 2020 [cited by applicant]
US 10695219B2 · Herchman et al. · 2020 [cited by applicant]
US 10869781B2 · Ha · 2020 [cited by applicant]
US 10973680B2 · Badawi et al. · 2021 [cited by applicant]
US 11007367B2 · O'Clock · 2021 [cited by applicant]
US 11172750B2 · Park et al. · 2021 [cited by applicant]
US 11213427B2 · Xiao · 2022 [cited by applicant]
US 11305118B2 · Rockley et al. · 2022 [cited by applicant]
US 11364380B2 · Goodall et al. · 2022 [cited by applicant]
US 20020026225A1 · Segal · 2002 [cited by applicant]
US 20050137649A1 · Paul, Jr. · 2005 [cited by applicant]
US 20080028214A1 · Tafoya et al. · 2008 [cited by applicant]
US 20080171929A1 · Katims · 2008 [cited by applicant]
US 20090048642A1 · Goroszeniuk · 2009 [cited by applicant]
US 20090099405A1 · Schneider et al. · 2009 [cited by applicant]
US 20100049180A1 · Wells et al. · 2010 [cited by applicant]
US 20100298863A1 · Hindinger et al. · 2010 [cited by applicant]
US 20110081333A1 · Shantha et al. · 2011 [cited by applicant]
US 20120203310A1 · Pugh et al. · 2012 [cited by applicant]
US 20140081369A1 · Sosa et al. · 2014 [cited by applicant]
US 20150018927A1 · Warschewske · 2015 [cited by applicant]
US 20160263376A1 · Yoo et al. · 2016 [cited by applicant]
US 20170027812A1 · Hyde et al. · 2017 [cited by applicant]
US 20170036009A1 · Hughes et al. · 2017 [cited by applicant]
US 20170106203A1 · Schneider et al. · 2017 [cited by applicant]
US 20180325729A1 · Rynerson · 2018 [cited by applicant]
US 20190046794A1 · Goodall et al. · 2019 [cited by applicant]
EP 3103507A1 · 2016 [cited by applicant]
WO 2014110575A1 · 2014 [cited by applicant]
WO 2014142970A1 · 2014 [cited by applicant]
WO 2018071630A1 · 2018 [cited by applicant]
Chaikin, et al., “Microcurrent stimulation in the treatment of dry and wet macular degeneration”, “Clinical Ophthalmology”, Dec. 2015, pp. 2345-2353, vol. 2015:9. [cited by applicant]
Fujikado, et al., “Effect of Transcorneal Electrical Stimulation in Patients with Nonarteritic Ischemic Optic Neuropathy or Traumatic Optic Neuropathy”, “Jpn J Ophthalmol”, May-Jun. 2006, pp. 266-273, vol. 50. [cited by applicant]
Groppa, et al., “A practical guide to diagnostic transcranial magnetic stimulation: Report of an IFCN committee”, “Clin. Neurophysiol.”, May 2012, pp. 858-882, vol. 123, No. 5. [cited by applicant]
Kloth, “Electrical Stimulation Technologies for Wound Healing”, “Advances in Wound Care”, Aug. 2014, pp. 81-90, vol. 3, No. 2. [cited by applicant]
Mayo Clinic, “Transcranial magnetic stimulation”, “www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625?p=1”, 1998. [cited by applicant]
Morimoto, et al., “Evaluation of residual retinal function by pupillary constrictions and phosphenes using transcorneal electrical stimulation in patients with retinal degeneration”, Mar. 21, 2006, pp. 1283-1292, vol. 2… [cited by applicant]
Wrobel, et al., “Therapy for Retinal Degeneration”, “Retina Today”, Oct. 2011, pp. 80-81. [cited by applicant]